CMS-NCI Pilot Project Trials
Status of CMS-NCI Colorectal Cancer Trials Under Medicare's National Coverage Decision—As of December 1, 2005.
On January 28, 2005, the Centers for Medicare and Medicaid Services (CMS) issued a national coverage decision (NCD) on certain off-label uses of four colorectal cancer colorectal cancer drugs.The NCD announced that CMS will cover the use of oxaliplatin (Eloxatin), irinotecan (Camptosar), cetuximab (Erbitux), or bevacizumab (Avastin), in nine clinical trials identified by CMS and sponsored by the National Cancer Institute (NCI). The NCD applies to traditional Medicare as well as Medicare plans provided through Health Maintenance Organizations (HMOs) and Preferred Provider Organizations (PPOs).
Coverage is provided for clinical care associated with Medicare patients who participate in the studies. As of December 20, 2005, four of the nine clinical trials have been activated. This chart will be updated as the status of the nine clinical trials changes.
Matt Farber, Manager, Provider Economics & Public Policy,Phone 301.984.9496, ext. 221, Email mfarber@accc-cancer.org
